HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.

Abstract
CD13 is a marker of angiogenic endothelial cells, and recently it is proved to be a biomarker of human liver cancer stem cells (CSCs). Herein, the therapeutic effects of NGR-LDP-AE, a fusion protein composed of CD13-targeting peptide NGR and antitumor antibiotic lidamycin, on human liver cancer and its mechanism were studied. Western blot and immunofluorescence assay demonstrated that CD13 (WM15 epitope) was expressed in both human liver cancer cell lines and vascular endothelial cells, while absent in normal liver cells. MTT assay showed that NGR-LDP-AE displayed potent cytotoxicity to cultured tumor cell lines with IC50 values at low nanomolar level. NGR-LDP-AE inhibited tumorsphere formation of liver cancer cells, and the IC50 values were much lower than that in MTT assay, indicating selectively killing of CSCs. In endothelial tube formation assay, NGR-LDP-AE at low cytotoxic dose significantly inhibited the formation of intact tube networks. Animal experiment demonstrated that NGR-LDP-AE inhibited the growth of human liver cancer xenograft. Immunohistochemical analysis showed that NGR-LDP-AE induced the down-regulation of CD13. In vitro experiment using cultured tumor cells also confirmed this result. NGR-LDP-AE activated both apoptotic and autophagic pathways in cultured tumor cells, while the induced autophagy protected cells from death. Conclusively, NGR-LDP-AE exerts its antitumor activity via killing liver CSCs and inhibiting angiogenesis. With one targeting motif, NGR-LDP-AE acts on both liver CSCs and angiogenic endothelial cells. It is a promising dual targeting fusion protein for liver cancer therapy, especially for advanced or relapsed cancers.
AuthorsYan-Bo Zheng, Jian-Hua Gong, Xiu-Jun Liu, Yi Li, Yong-Su Zhen
JournalMolecular carcinogenesis (Mol Carcinog) Vol. 56 Issue 5 Pg. 1395-1404 (05 2017) ISSN: 1098-2744 [Electronic] United States
PMID27991698 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2017 Wiley Periodicals, Inc.
Chemical References
  • Antineoplastic Agents
  • NGR peptide
  • Oligopeptides
  • Recombinant Proteins
  • CD13 Antigens
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Autophagy (drug effects)
  • CD13 Antigens (metabolism)
  • Cell Line, Tumor
  • Female
  • Humans
  • Liver (blood supply, drug effects, pathology)
  • Liver Neoplasms (drug therapy, pathology)
  • Mice, Nude
  • Molecular Targeted Therapy (methods)
  • Neoplastic Stem Cells (drug effects)
  • Neovascularization, Pathologic (drug therapy)
  • Oligopeptides
  • Recombinant Proteins (pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: